Evidence‐Based Review of Therapies in Multiple Myeloma

This chapter contains sections titled: Questions Literature‐search strategy and inclusions In patients who are to undergo autologous transplantation as initial therapy is dexamethasone with thalidomide superior to dexamethasone alone as initial therapy for untreated multiple myeloma? Does the addition of thalidomide to melphalan and prednisone improve outcomes in untreated patients? Recommendation Does high dose therapy followed by stem cell transplant improve outcomes compared with conventional therapy? Is bortezomib superior to dexamethasone in relapsed/refractory myeloma? Recommendations What is the role of lenalidomide in patients with relapsed or refractory myeloma? References Questions Literature‐search strategy and inclusions In patients who are to undergo autologous transplantation as initial therapy is dexamethasone with thalidomide superior to dexamethasone alone as initial therapy for untreated multiple myeloma? Does the addition of thalidomide to melphalan and prednisone improve outcomes in untreated patients? Recommendation Does high dose therapy followed by stem cell transplant improve outcomes compared with conventional therapy? Is bortezomib superior to dexamethasone in relapsed/refractory myeloma? Recommendations What is the role of lenalidomide in patients with relapsed or refractory myeloma? References